Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13989416 | 0.88 | CYP1A2 (0.57) | KDM4EALDH1A1L3MBTL1CYP1A2MEN1 | |
| SCHEMBL30486824 | 0.87 | CYP1A2 (0.52) | KDM4EALDH1A1L3MBTL1CYP1A2ESR1 | |
| SCHEMBL8830006 | 0.87 | PSMB5 (0.57) | KDM4EALDH1A1L3MBTL1CYP1A2MEN1 | |
| SCHEMBL29692924 | 0.87 | PSMB5 (0.57) | KDM4EALDH1A1L3MBTL1CYP1A2MEN1 | |
| SCHEMBL4859835 | 0.87 | CYP1A2 (0.52) | KDM4EALDH1A1L3MBTL1CYP1A2ESR1 | |
| SCHEMBL29645268 | 0.85 | CYP1A2 (0.50) | KDM4EALDH1A1L3MBTL1CYP1A2ESR1 | |
| SCHEMBL28507783 | 0.85 | CYP1A2 (0.50) | KDM4EALDH1A1L3MBTL1CYP1A2ESR1 | |
| SCHEMBL28895496 | 0.85 | CYP1A2 (0.50) | KDM4EALDH1A1L3MBTL1CYP1A2ESR1 | |
| SCHEMBL29708951 | 0.85 | CYP1A2 (0.50) | KDM4EALDH1A1L3MBTL1CYP1A2ESR1 | |
| SCHEMBL28051566 | 0.83 | CYP1A2 (0.67) | KDM4EALDH1A1L3MBTL1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10957869-B2 | Organic luminescent materials containing cycloalkyl ancillary ligands | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2021-03-23 | — | — | US | disclosed |
| US-20190103574-A1 | ORGANIC LUMINESCENT MATERIALS CONTAINING CYCLOALKYL ANCILLARY LIGANDS | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2019-04-04 | — | — | US | disclosed |
| US-20190077818-A1 | ORGANIC LUMINESCENT MATERIALS CONTAINING FLUORINE ANCILLARY LIGANDS | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2019-03-14 | — | — | US | disclosed |
| EP-2168968-B1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-2168968-B1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| CN-102924458-B | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC | 2014-11-05 | — | — | CN | disclosed |
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8653268-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-02-18 | — | — | US | disclosed |
| WO-2007064993-A2 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064993-A2 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| CN-1960993-A | 6, 6-bicyclic substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC (US) | 2007-05-09 | — | — | CN | disclosed |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC., | 2007-02-08 | — | — | US | disclosed |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC., | 2007-02-08 | — | — | US | disclosed |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC., | 2007-02-08 | — | — | US | disclosed |
| EP-1740591-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
| WO-2005097800-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-5627193-A | MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190103574-A1 | ORGANIC LUMINESCENT MATERIALS CONTAINING CYCLOALKYL ANCILLARY LIGANDS | ACAT1, ACACA, ACAT2 | KDM4E 4362/4885ALDH1A1 42/4885L3MBTL1 2059/4885 |
| US-10957869-B2 | Organic luminescent materials containing cycloalkyl ancillary ligands | ACAT1, ACACA, ACAT2 | KDM4E 4362/4885ALDH1A1 42/4885L3MBTL1 2059/4885 |
| US-20190077818-A1 | ORGANIC LUMINESCENT MATERIALS CONTAINING FLUORINE ANCILLARY LIGANDS | FOXO1, NAA15, FOXK1 | KDM4E 3879/4885ALDH1A1 16/4885L3MBTL1 1986/4885 |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | IGF1R, BRCA1, MAP2K6 | KDM4E 2865/4885ALDH1A1 3270/4885L3MBTL1 3679/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | KDM4E 2218/4885ALDH1A1 3941/4885L3MBTL1 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.